UNS unilife corporation
Add to My Watchlist 0.00% ! 0.5¢

must be close

  1. gavin0909
    166 Posts.
    clock Created with Sketch.
    19/06/13
    12:23
    Post #: 11902672

    July 1, 2008

    Unilife Signs an Exclusive License Agreement with sanofi-aventis

    Key Points:
    •Sanofi-aventis secures exclusive rights to the Unilife Ready-to-Fill Syringe for five years
    •Unilife to receive an upfront license fee of A$16.4 million (€10 million) fromsanofi-aventis
    •Unilife and sanofi-aventis to negotiate in good faith to finalise an agreement to complete industrialisation of the licensed product under which sanofiaventis will bear the industrialisation costs initially estimated at A$24 to $27 million (€15 to €17 million)
    UNS Price at posting: 57.0¢ Sentiment: None Disclosure: Held
    Likes Created with Sketch. 13  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

VMM Colossus PFS Unlocks World-Class Project Economics and Positions Viridis for Global Leadership
right-arrow Created with Sketch.
NEWS Activeport Secures Network Transformation Contract with Ishan Technologies
right-arrow Created with Sketch.
NEWS Trump just dropped a 200% tariff bomb. Here's how to cash in
right-arrow Created with Sketch.
NEWS Copper and Base Metals Targets Confirmed at Minbrie with Drilling Ahead
right-arrow Created with Sketch.
HAR Maiden Drilling Program to Commence at Ibel South Gold Project
right-arrow Created with Sketch.
NEWS Blue Moon first wedge hole intersects 543g/t gold over 1.2m in laminated quartz vein
right-arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.